임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

23건 표시

2상모집 중· Cytokine Release Syndrome
Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
협력: 얀센(J&J)
상세 →NCT07657312
2상모집 중· Multiple Myeloma
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
리드: 얀센(J&J)
상세 →NCT07589634
2상모집 중· Carcinoma, Non-Small-Cell Lung
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
리드: 얀센(J&J)
상세 →NCT07586202
2상모집 중· Cancer
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
협력: 얀센(J&J)
상세 →NCT06807593
2상모집 중· Multiple Myeloma
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
리드: 얀센(J&J)
상세 →NCT07266441
2상모집 중· Dermatitis, Atopic
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
리드: 얀센(J&J)
상세 →NCT07230860
2상모집 중· Arthritis, Psoriatic
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
리드: 얀센(J&J)
상세 →NCT07321873
2상모집 중· Multiple Myeloma (MM)
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
협력: 얀센(J&J)
상세 →NCT07107529
2상모집 중· Multiple Myeloma in Relapse
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
협력: 얀센(J&J)
상세 →NCT06827860
2상모집 중· Multiple Myeloma
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
리드: 얀센(J&J)
상세 →NCT07149857
2상모집 중· AL Amyloidosis
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
협력: 얀센(J&J)
상세 →NCT06649695
2상모집 중· Carcinoma, Non-Small-Cell Lung
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
리드: 얀센(J&J)
상세 →NCT06667076
2상모집 중· Geographic Atrophy
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
리드: 얀센(J&J)
상세 →NCT06635148
2상모집 중· Multiple Myeloma
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
리드: 얀센(J&J)
상세 →NCT06500884
2상모집 중· Multiple Myeloma
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
협력: 얀센(J&J)
상세 →NCT06505369
2상모집 중· Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
리드: 얀센(J&J)
상세 →NCT05963074
2상모집 중· Pulmonary Tuberculosis
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
협력: GSK, 얀센(J&J)
상세 →NCT06114628
2상모집 중· Multiple Myeloma
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
협력: 얀센(J&J)
상세 →NCT05572229
2상모집 중· Multiple Myeloma
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
협력: 얀센(J&J)
상세 →NCT05695508
2상모집 중· Carcinoma, Non-small-Cell Lung
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
리드: 얀센(J&J)
상세 →NCT05498428
2상모집 중· High-risk Smoldering Multiple Myeloma
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
협력: 얀센(J&J)
상세 →NCT05469893
2상모집 중· Hematological Malignancies
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
리드: 얀센(J&J)
상세 →NCT04634552
2상모집 중· Tuberculosis, Multidrug-Resistant
Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB
리드: 얀센(J&J)
상세 →NCT02354014

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.